Desentum (private company)

See something wrong or missing? Let us know
Offices:
Espoo
Category:
Biotech Pharma
Business model:
B2B
Key People:
Pekka Mattila
Investors:
we tracked 5 investors
You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Total investments received (USD) - we tracked 2 transactions

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergen immunotherapy products that are based on switching the immune system's response to allergens from hypersensitivity to tolerance.

We have a unique approach for designing the hypoallergens used in immunotherapy. By studying the molecular mechanism of the hypersensitivity reaction, we have made discoveries that allow for improved design of immunotherapeutic products against common types of allergies.

Our goal is to provide long-term relief for patients suffering from allergic symptoms, as well as reduce the social and economic burden allergies cause to both individuals and society.

Companies with similar profile to Desentum:

CompanyCriteria
Finland BioMensio
45%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: VTT Ventures
  • Minim one investor from outside Scandinavia: Yes
Finland Minima Processor
44%
  • Similar business models: B2B
  • At least one vc investor: VTT Ventures
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Finland LymphaTouch
44%
  • Similar business models: B2B
  • At least one vc investor: ACME Investments
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Sweden Gradientech
44%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
Finland Asqella
44%
  • Similar business models: B2B
  • At least one vc investor: VTT Ventures
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Sweden OxThera
44%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Denmark Cirqle Biomedical
44%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Finland Aiforia
44%
  • Similar business models: B2B
  • At least one vc investor: ACME Investments, Sto-Rahoitus Oy
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Denmark AFYX Therapeutics
44%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Denmark STipe Therapeutics
44%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Denmark NMD Pharma
44%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Sweden ITBMed
44%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Finland Mobidiag
43%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one other investor: Springvest Oy
  • Minim one investor from outside Scandinavia: Yes
Denmark Biosyntia
43%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Denmark CysBio
43%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Norway Sorbwater Technology
43%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Sweden Monocl
43%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Finland Solar Foods
35%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: VTT Ventures
Sweden Quretech Bio
34%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
Sweden Athera
34%
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B